Switching to entecavir reduces relapse, flare in HBeAg-negative patients
In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.
Switching to entecavir reduces relapse, flare in HBeAg-negative patients
06 Jul 2026
